beta

ANAB

AnaptysBio, Inc.

Anab

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Market Cap: 380 Million

Primary Exchange: NASDAQ

Website: http://www.anaptysbio.com

Shares Outstanding: 27.1 Million

Float: 24.1 Million

Dividend: (%)

Beta: 1.43139488944874

Sector: Health Technology

Industry: Biotechnology

Ethical Flags

Animal testing

Longest drawdown: 476 trading days

From: 2018-03-02 To: 2019-12-06

Lowest Point:

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2019 Update

via: SeekingAlpha at 2019-06-12 01:06:09:000

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Ole Andreas Halvorsen… read more...

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2019 Update

via: SeekingAlpha at 2019-06-12 01:06:09:000

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Ole Andreas Halvorsen… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud